{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:41:52Z","timestamp":1794710512203,"version":"4.9.1"},"reference-count":21,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,5,22]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This post hoc analysis assessed the effect of baseline C-reactive protein (CRP) on the efficacy and safety of tofacitinib (TOF) use in ankylosing spondylitis (AS), as well as patient-reported outcomes (PROs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Phase II (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01786668\">NCT01786668<\/jats:ext-link>) and phase III (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03502616\">NCT03502616<\/jats:ext-link>) data from patients with active AS were used. Endpoints (weeks 12, 16, and 48), including 20% and 40% improvement in Assessment of SpondyloArthritis international Society (ASAS), AS Disease Activity Score with CRP low disease activity, 50% improvement in Bath AS Disease Activity Index (BASDAI50), and PROs (pain and fatigue), were stratified by baseline CRP (mg\/L) as follows: &lt; 5 (normal), \u2265 5 (elevated), &lt; 10, and \u2265 10. Safety outcomes were evaluated between &lt; 5 and \u2265 5 mg\/L subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 372 patients were included (69.6% \u2265 5mg\/L; 50.8% \u2265 10 mg\/L). At baseline in the &lt; 5mg\/L group, more placebo-treated than TOF-treated patients received concomitant nonsteroidal antiinflammatory drugs (NSAIDs) or sulfasalazine (SSZ). Week 12 efficacy and PRO responses were generally higher for TOF vs placebo, regardless of baseline CRP. The treatment effect (placebo-adjusted response) at week 12 was generally numerically higher in \u2265 5 mg\/L and \u2265 10 mg\/L vs &lt; 5 mg\/L and &lt; 10 mg\/L groups. Incidence rates for treatment-emergent adverse events (TEAEs) and \u201call infections\u201d were numerically higher for TOF vs placebo in patients in the &lt; 5 mg\/L group, but similar for TOF vs placebo in patients in the \u2265 5 mg\/L group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Regardless of baseline CRP, TOF was more efficacious vs placebo at week 12. The placebo-adjusted efficacy and PRO responses were generally numerically higher in patients with CRP \u2265 5 mg\/L and \u2265 10 mg\/L vs &lt; 5 mg\/L and &lt; 10 mg\/L. The higher concomitant NSAID\/SSZ exposure may have improved efficacy responses in the baseline &lt; 5 mg\/L placebo group, and ultimately affected the TOF treatment effect. Safety was consistent with previous studies of TOF use in AS, with numerically higher incidence rates for TEAEs and \u201call infections\u201d for TOF vs placebo in patients with CRP &lt; 5 mg\/L.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-1198","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T14:30:26Z","timestamp":1717338626000},"page":"772-780","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-5336","authenticated-orcid":false,"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3052-3822","authenticated-orcid":false,"given":"Amit V.","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya Kiran","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Cadatal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"key":"2024080105251902000_51.8.772.1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G"},{"key":"2024080105251902000_51.8.772.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2024080105251902000_51.8.772.3","first-page":"263","article-title":"Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature","volume":"36","author":"Bohn","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2024080105251902000_51.8.772.4","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/rheumatology\/key079","article-title":"Axial spondyloarthritis including ankylosing spondylitis","volume":"57","author":"Braun","year":"2018","journal-title":"Rheumatology"},{"key":"2024080105251902000_51.8.772.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21619"},{"key":"2024080105251902000_51.8.772.6","first-page":"991","article-title":"Fatigue in ankylosing spondylitis\u2014why is it ignored?","volume":"20","author":"Calin","year":"1993","journal-title":"J Rheumatol"},{"key":"2024080105251902000_51.8.772.7","first-page":"e42528","article-title":"Spinal mobility limitation can be the main reason of kinesiophobia in ankylosing spondylitis","volume":"15","author":"Sari","year":"2023","journal-title":"Cureus"},{"key":"2024080105251902000_51.8.772.8","doi-asserted-by":"crossref","first-page":"2249822","DOI":"10.1080\/07853890.2023.2249822","article-title":"The effectiveness of hippotherapy simulation exercises for muscle strength, disease activity and quality of life in sedentary adults with ankylosing spondylitis","volume":"55","author":"Salba\u015f","year":"2023","journal-title":"Ann Med"},{"key":"2024080105251902000_51.8.772.9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11926-020-00932-5","article-title":"Work disability in axial spondyloarthritis","volume":"22","author":"Nikiphorou","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2024080105251902000_51.8.772.10","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12779"},{"key":"2024080105251902000_51.8.772.11","doi-asserted-by":"crossref","first-page":"e0211946","DOI":"10.1371\/journal.pone.0211946","article-title":"Baseline high-sensitivity C-reactive protein predicts the risk of incident ankylosing spondylitis: results of a community-based prospective study","volume":"14","author":"Su","year":"2019","journal-title":"PLOS One"},{"key":"2024080105251902000_51.8.772.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"2024080105251902000_51.8.772.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"2024080105251902000_51.8.772.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.24838"},{"key":"2024080105251902000_51.8.772.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.147744"},{"key":"2024080105251902000_51.8.772.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160003"},{"key":"2024080105251902000_51.8.772.17","first-page":"0904","article-title":"Response to ixekizumab by C-reactive protein level in patients with radiographic axial spondyloarthritis: results from the COAST-V (biological-na\u00efve) and COAST-W (TNF inhibitor-experienced) trials at 52 weeks [abstract]","volume":"72","author":"Reveille","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024080105251902000_51.8.772.18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000749"},{"key":"2024080105251902000_51.8.772.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"2024080105251902000_51.8.772.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"2024080105251902000_51.8.772.21","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/rheumatology\/keac104","article-title":"Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-1198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:36:46Z","timestamp":1722515806000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-1198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.3899\/jrheum.2023-1198"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-1198","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}